摘要
目的探讨索拉非尼对顺铂抑制肝癌细胞HepG2增殖的影响及其可能机制。方法分别及联合应用两药后以MTT法检测HepG2细胞的增殖抑制,用流式细胞术检测细胞凋亡,用RT-PCR检测MDR-1的mRNA表达。结果索拉非尼及DDP单药对HepG2均有抑制作用,两药联合具有协同或相加作用。联合用药细胞凋亡率明显高于单药组(P<0.05)。单药顺铂组与联合组MDR-1的mRNA表达高于对照组及索拉非尼单药组,其中单药顺铂组表达最高(P<0.05)。结论索拉非尼联合顺铂对肝癌HepG2细胞有更强的抑制及促凋亡作用,其机制可能与增加HepG2细胞的凋亡,索拉非尼下调MDR-1,增强顺铂对HepG2细胞的诱导凋亡作用有关。
Objective To evaluate the effect of Sorafenib on cisplatin（DDP）-induced apoptosis of hepatocellular carcinoma cells, and to study the mechanistic actions of Sorafenib. Method The effects of Sorafenib, DDP, or Sorafenib＋DDP on the proliferation,cell cycle progression, apoptosis and the mRNA expression of MDR-1 of HepG2 cell were studied using MTT assay, flow cytometry and RT-PCR, respectively. Result Sorafenib or DDP can inhibit the proliferation of HepG2 cells. Sorafenib acts synergistically with DDP in both growth inhibition and in induction of apoptosis of HepG2 cells （P〈0.05）. The level of MDR-1 mRNA expressions was in the order of DDP-treated 〉DDP＋ Sorafenib-treated 〉Sorafenib-treated HepG2 cells （P〈0.05）. Conclusion Sorafenib combined with DDP showed a synergistic growth inhibition and induction of apoptosis in HepG2 cells. The effect was correlated with the down-regulation of MDR-1 by Soratenib.
出处
《热带医学杂志》
CAS
2008年第4期306-308,共3页
Journal of Tropical Medicine
关键词
索拉非尼
顺铂
肝癌
联合
Sorafenib
cisplatin
hepatocellular carcinoma
combination
